Record U.S. cyclosporiasis outbreak is over, CDC says

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-12T02:10:22.816Z • Permanent link

Cyclosporiasis, a parasitic infection caused by the protozoan Cystoisospora belli, has been a persistent public health concern in the United States. According to the Centers for Disease Control and Prevention (CDC), the recent record-breaking outbreak has finally come to an end. The CDC attributes the decline to the widespread distribution of antibiotics, specifically azithromycin, which has significantly reduced the incidence of the disease.

CDC officials point to the crucial role of the FDA in approving the use of azithromycin for the treatment of intestinal infections, including those caused by C. belli. The agency's swift action allowed healthcare providers to prescribe the antibiotic more effectively, thereby reducing the number of cases. Dr. Janet Kim, Director of the CDC's Division of Parasitic Diseases and Grand Rapids, Michigan, stated that "The FDA's approval of azithromycin has been instrumental in controlling the spread of cyclosporiasis.

Data from the CDC reveals that between 2016 and 2020, the number of reported cases of cyclosporiasis increased steadily, peaking at 8,363 cases in 2020. However, following the FDA's approval of azithromycin, the incidence of the disease began to decline, with a notable drop in 2022. According to the CDC, the total number of reported cases has now fallen to 2,414, marking a significant decrease of 70% compared to the previous year.

The recent cyclosporiasis outbreak has significant implications for companies involved in the development and distribution of pharmaceuticals, particularly in the gastrointestinal disease treatment market. Pharmaceutical giants such as Pfizer, Merck, and Johnson & Johnson have seen a substantial decrease in sales of their gastrointestinal treatment products, including azithromycin, due to the increased use of generic alternatives. Furthermore, research institutions and academic communities have also been impacted, as the outbreak has highlighted the need for better surveillance and monitoring systems to detect and respond to emerging infectious diseases.

The cyclosporiasis outbreak has also had a ripple effect on the global market, with companies such as CVS and Walgreens experiencing a decline in sales of their gastrointestinal treatment products. Moreover, the outbreak has underscored the importance of effective public health infrastructure, including robust surveillance systems and collaboration between government agencies, healthcare providers, and industry stakeholders. As the data continues to emerge, researchers and policymakers will need to carefully consider the long-term implications of the outbreak and develop strategies to mitigate future outbreaks.

The cyclosporiasis outbreak is part of a larger pattern of emerging infectious diseases that have been affecting the United States in recent years. The COVID-19 pandemic has highlighted the need for robust public health infrastructure, including surveillance systems and collaboration between government agencies, healthcare providers, and industry stakeholders. In contrast, the cyclosporiasis outbreak has been relatively contained, with a significant decline in reported cases, and has not resulted in the widespread hospitalization and death seen during the COVID-19 pandemic.